Current recommendations for the indication of HCT for the treatment of patients with MF and proposed variables to assess the risk
| Current MF patient selection for allo-HCT∗ . | Parameters for consideration in proposed allo-HCT risk stratifier† . |
|---|---|
| pMF and intermediate-2 or high-risk DIPSS or high-risk MIPSS70+ and low or intermediate MTSS | Age |
| HCT-CI score | |
| sMF and intermediate-2 or high-risk sMF prognostic model score | Karnofsky Performance Status |
| Leukocytes (109/L) | |
| Blood blasts (%) | |
| pMF and intermediate-1 DIPSS or intermediate MIPSS70+ with low MTSS and a balance of patient preferences and treatment options | Hemoglobin (g/dL) |
| Platelets (109/L) | |
| Donor type | |
| Patients >70 y on an individual basis | Type of conditioning |
| Type of GVHD prophylaxis |
| Current MF patient selection for allo-HCT∗ . | Parameters for consideration in proposed allo-HCT risk stratifier† . |
|---|---|
| pMF and intermediate-2 or high-risk DIPSS or high-risk MIPSS70+ and low or intermediate MTSS | Age |
| HCT-CI score | |
| sMF and intermediate-2 or high-risk sMF prognostic model score | Karnofsky Performance Status |
| Leukocytes (109/L) | |
| Blood blasts (%) | |
| pMF and intermediate-1 DIPSS or intermediate MIPSS70+ with low MTSS and a balance of patient preferences and treatment options | Hemoglobin (g/dL) |
| Platelets (109/L) | |
| Donor type | |
| Patients >70 y on an individual basis | Type of conditioning |
| Type of GVHD prophylaxis |